维生素A辅助治疗小儿支气管哮喘的效果及对血清转化生长因子β1、嗜酸性粒细胞、白细胞介素17水平的影响  

Efficacy of vitamin A adjuvant therapy on bronchial asthma in children and its influence on serum transforming growth factor-β1,eosinophils and interleukin-17 levels

作　　者：侯红红[1] 孙艳[1] 潘建丽[2] 罗志娟[1] 李莎莎 刘颖 Hou Honghong;Sun Yan;Pan Jianli;Luo Zhijuan;Li Shasha;Liu Ying(Department of Pediatrics,Xi'an Central Hospital,Xi'an 710000,China;Department of Pediatrics,Xi'an Children's Hospital,Xi'an 710000,China)

机构地区：[1]陕西省西安市中心医院儿科,西安710000 [2]陕西省西安市儿童医院儿科,西安710000

出　　处：《中国综合临床》2025年第1期20-26,共7页Clinical Medicine of China

基　　金：陕西省自然科学基础研究计划项目(2022JQ-858)。

摘　　要：目的探讨维生素A辅助治疗小儿支气管哮喘的临床效果及对血清转化生长因子β1(transforming growth factor-β1)、嗜酸性粒细胞(eosinophils,EOS)、白细胞介素17(interleukin-17,IL-17)水平的影响。方法选取2022年1月至2023年12月于西安市中心医院儿科接受治疗的110例小儿支气管哮喘患儿临床资料进行前瞻性研究,根据组间基线特征均衡可比的原则,按照随机数字表法随机分为对照组和观察组各55例。对照组予以常规小儿支气管哮喘治疗,观察组在对照组基础上予以维生素A辅助治疗。连续治疗15 d后,评估两组患儿哮喘控制情况[儿童哮喘控制测试(childhood-asthma control test,C-ACT)、哮喘控制问卷(asthma control questionnaire,ACQ)];比较两组患儿治疗前和治疗15 d后,肺通气功能[第1秒用力呼气容积(forced expiratory volume in one second,FEV_(1))、FEV_(1)/用力肺活量(forced expiratory volume in one second/forced vital capacity,FEV_(1)/FVC)、呼气峰流量(peak expiratory flow,PEF)]及血清炎症因子(TGF-β1、EOS、IL-17)水平及免疫功能指标[辅助性T细胞17(T-helper 17 cells,Th17)、辅助性T细胞2(T-helper 2 cells,Th2)、调节性T细胞(regulatory T cells,Treg)]水平。符合正态或近似正态分布的计量资料以xˉ±s表示,组间比较采用独立样本t检验;计数资料以百分比表示,组间比较采用χ^(2)检验。结果观察组患儿治疗15 d后的C-ACT评分[(16.20±3.14)分]高于对照组[(14.80±2.62)分],ACQ评分[(30.30±4.14)分]低于对照组[(34.60±6.23)分],组间比较差异均有统计学意义(t值分别为2.54和4.26;P值分别为0.012和<0.001)。治疗15 d后,观察组和对照组患儿肺通气功能指标[FEV1:(1.76±0.34)L与(1.54±0.32)L、FEV1/FVC:(76.89±5.76)%与(70.25±6.42)%、PEF(2.89±0.35)L/s与(2.68±0.39)L/s]均高于治疗前[FEV1:(1.12±0.31)L与(1.20±0.33)L、FEV1/FVC:(56.96±4.35)%与(58.12±3.48)%、PEF(2.15±0.66)L/s与(2.34±0.56)L/s],差异有统计学意义(t值分别为ObjectiveTo explore the clinical effect of vitamin A in the adjuvant treatment of bronchial asthma in children and its influence on serum transforming growth factor-β1(TGF-β1),eosinophils(EOS)and interleukin-17(IL-17)levels.MethodsA prospective study was conducted on 110 children with bronchial asthma who received treatment in Department of Pediatrics,Xi'an Central Hospital from January 2022 to December 2023.Based on the principle of balanced and comparable baseline characteristics between groups,they were randomly divided into a control group and an observation group,with 55 cases in each group,using a random number table method.The control group was treated with routine pediatric bronchial asthma therapy,while the observation group was added with vitamin A adjuvant therapy on the basis of the control group.After 15 days of continuous treatment,the scores of asthma control condition(Childhood-Asthma Control Test(C-ACT),Asthma Control Questionnaire(ACQ))in the two groups were evaluated.The pulmonary ventilation function(forced expiratory volume in one second(FEV 1),forced expiratory volume in one second/forced vital capacity(FEV 1/FVC),peak expiratory flow(PEF)),serum inflammatory factors(TGF-β1,EOS,IL-17)and immune function indicators(T helper 17 cell(Th17),T helper 2 cell(Th2),regulatory T cell(Treg))were compared between groups of children before treatment and after 15 days of treatment.Measurement data with normal or approximate distribution were expressed as x¯±s,and independent sample t test was used for comparison between groups.Enumeration data were expressed as percentage,and chi-square test was adopted for between-group comparison.ResultsAfter 15 days of treatment,the C-ACT score with(16.20±3.14)points in observation group was higher than(14.80±2.62)points in control group while the ACQ score with(30.30±4.14)points was lower than(34.60±6.23)points in control group,with statistical differences between groups(t values were 2.54 and 4.26;P values were 0.012 and<0.001).The pulmonary ventilation fun

关 键 词：维生素A 儿童 支气管哮喘 转化生长因子Β1 嗜酸性粒细胞 白细胞介素17 

分 类 号：R56[医药卫生—呼吸系统]